Official employment data in the United States for June must be made public Thursday afternoon. They should shed light on the trajectory of the levels of the American Federal Reserve (Fed). “According to the consensus carried out by Bloomberg, analysts expect 111,000 new non -agricultural jobs, a slight slowdown in monthly wage growth and an increase in unemployment rate from 4.2% to 4.3%,” reports Ipek Ozkardeskaya, analyst at Swissquote.
In Switzerland, inflation rebounded in June. Consumer prices increased by 0.1% over one year and 0.2% compared to the previous month, according to the Federal Statistics Office (FSA).
“Outside rents, inflation in Switzerland would be negative at -0.5% over a year, translating a situation of deflation on almost all of other goods and services,” notes Arthur Jurus, director of investments at ODDO BHF Switzerland, in a comment. For the expert, even in a context of generalized disinflation, the increase in rents prevents the consumer price index (IPC) from plunging, making housing costs the main focus of inflation in Switzerland and leaving the persistence of inflationary pressures as long as the housing crisis is not resolved.
On the Swiss Stock Exchange, the SMI star index was nibbled around 11 a.m. 0.07% to 12,000.35 points. SLI earned 0.12 % % at 1971.82 points. The spinnaker took 0.08% to 16,638.30 points. Of the thirty-one star values, fifteen advanced and sixteen retreated.
Zurich Insurance (+1.2%) took the lead in the provisional classification.
Swiss Re (+1.1%) and SGS (+1.0%) completed the podium. The chocolate medal was allocated to UBS (+1.0%).
Nestlé (+0.6%) also expanded his earnings. Bank of America noted the price of giant Veveysan of food at 100 francs, against 97 francs previously.
The good rock (-0.04%) weighed on the other hand on the index. Vontobel lowered the target of the Rhénan laboratory at 303 francs, against 320 francs previously.
On the losers side, we also found Sonova (-0.5%) and Straumann (-0.8%).
Novartis (-0.8%) fell into the back of the ranking. The Basel pharmaceutical giant announced the failure in phase III of its cosentyx medication intended for the treatment of adults with giant cell arteritis (ACG) newly diagnosed or recurrent.
The Evolva action took 0.4%. The former Biochemist Rhénan will propose on July 25 to its shareholders to adopt the corporate name Evonext, during an extraordinary general meeting.
On the other hand, the cantonal bank of Basel-Campagne (BLKB) lost the gains acquired at the start of the session (-1.7%). The BLKB warned that it has scored a new value of the value, of 105.5 million francs, on its participation in a radicant. The establishment announced in the wake the withdrawal of its managing director for the end of March 2026 and the president of his bank council for the end of July 2026. (AWP)
